1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

23 Jul 2024
Admin
News Article

Grünenthal Acquires US-Company Valinor Pharma for Approx. $250 Million

Overview

Grünenthal, a global leader in pain management and related diseases, announced the acquisition of US-based Valinor Pharma, LLC (Valinor) and its product Movantik (naloxegol), with a total deal value of approx. $250 million inclusive of all royalty obligations. Grünenthal will finance the transaction using available liquidity.

Movantik: Indication

Movantik is indicated for the oral treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
The transaction further expands Grünenthal’s portfolio of established medicines and adds to the company’s growing US business.
Gross sales from Movantik in the United States reached over $200 million in 2023.

Words from the CEO: Grünenthal

“As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio”, says Gabriel Baertschi, CEO, Grünenthal.
“The acquisition of Valinor Pharma strengthens our footprint in the United States, the most important growth market for Grünenthal.”

Words from President: Grünenthal Us

Marv Kelly, president of Grünenthal US, commented: “We are excited to welcome Valinor and expand our portfolio offering to pain specialists with Movantik.”

Grünenthal acquired the product in Europe (branded Moventig outside of the US) in 2023 as part of a joint venture with Kyowa-Kirin. The acquisition of Valinor makes Grünenthal the worldwide owner of the brand (ex-Canada).

Acquisition of Established Medicines

With Movantik, Grünenthal continues to execute its strategy of acquiring established medicines to expand its portfolio and increase the company's profitability.
Since 2017, Grünenthal has acquired several established medicines, including Nebido, the European rights to Crestor and Nexium, as well as the global rights to Vimovo (excluding the US and Japan), Qutenza and Zomig (excluding Japan).
In 2023, Grünenthal established Grünenthal Meds, a joint venture with Kyowa Kirin International, which manages a portfolio of 13 brands primarily focused on pain management.

Grünenthal has invested more than €2 billion in successful M&A transactions.

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, it has a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!